Literature DB >> 34937517

The effectiveness of resveratrol in treatment of PCOS on the basis of experimental model in rats.

Maria Yarmolinskaya1,2, Olga Bulgakova1, Elena Abashova1, Valentina Borodina1, Tatyana Tral1,3.   

Abstract

PURPOSE OF THE STUDY: Polycystic ovary syndrome (PCOS) is a widespread endocrine disorder in women of reproductive age. Further research is required to justify new directions of effective targeted therapy of this condition. Resveratrol possesses anti-inflammatory, antioxidant and antidiabetic properties. The purpose of this study was to evaluate the potential effectiveness of resveratrol in PCOS based on the created model of this disease in Wistar rats.
MATERIALS AND METHODS: The PCOS model was created by oral administration of letrozole to female Wistar rats.. The animals received resveratrol at a dosage of 20 mg/kg and 30 mg/kg for the next 30 days. Then ovariectomy was performed for histological confirmation of the effectiveness of resveratrol in the treatment of PCOS. Regularity of estrous cycle, animal's body mass and the level of soluble receptors for advanced glycation end products (sRAGE) in the blood of rats were also evaluated in dynamics.
RESULTS: The study revealed that administration of resveratrol leads to dose-dependent restoration of normal morphology of ovarian tissue, normalizes regularity of estrous cycle and decreases body weight of rats with PCOS.
CONCLUSION: The results obtained in rats suggest that resveratrol may be a promising agent for the treatment of PCOS in women.

Entities:  

Keywords:  PCOS; glycation end products; resveratrol; soluble receptors for advanced glycation end products (sRAGE)

Mesh:

Substances:

Year:  2021        PMID: 34937517     DOI: 10.1080/09513590.2021.2014665

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  1 in total

1.  Biochemical Investigation of Therapeutic Potentials of Plant-Based Bioactive Compounds as Stimulators of Glucagon like peptide-1 Secretion.

Authors:  Areeba Javed; Ayman Muzammal; Muhammad Sajid Hamid Akash; Kanwal Rehman
Journal:  Dose Response       Date:  2022-07-08       Impact factor: 2.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.